Skip to main content
. Author manuscript; available in PMC: 2020 Oct 6.
Published in final edited form as: Nat Chem Biol. 2020 Apr 6;16(6):635–643. doi: 10.1038/s41589-020-0506-0

Fig. 3 |. DCLK1 is a target of aberrant KRAS-ERK signaling and is dispensable in DCLK1+ PDAC cell lines.

Fig. 3 |

(a) Immunoblot analysis of the indicated cell lines. (b) Immunoblot analysis of PATU-8988T FKBP12F36V-KRASG12V; KRAS−/− clone treated with DMSO or dTAG-13 for the indicated time-course. Data in a-b are representative of n = 3 independent experiments. Uncropped immunoblots for a-b are displayed in Supplementary Fig. 18. (c) DMSO-normalized antiproliferation of PATU-8988T (top) or PATU-8902 (bottom) LACZ-FKBP12F36V or FKBP12F36V-KRASG12V; KRAS−/− clones treated with DMSO or dTAG-13 for 120 h. Cells were cultured as 2D-adherent monolayers or as ultra-low adherent 3D-spheroid suspensions. Data are presented as mean ± S.D. of n = 4 biologically independent samples and are representative of n = 3 independent experiments. (d) Immunoblot analysis of PATU-8988T FKBP12F36V-KRASG12V; KRAS−/− clone treated with DMSO or dTAG-13 for the indicated time-course. (e) Immunoblot analysis of PATU-8988T cells treated with DMSO or trametinib for 48 h. Data in d-e are representative of n = 3 independent experiments. Uncropped immunoblots for d are displayed in Supplementary Fig. 18 and uncropped immunoblots for e are displayed in Supplementary Fig. 19. (f-g) DMSO-normalized antiproliferation of PATU-8988T cells treated with the indicated compounds for 120 h. Cells were cultured as 2D-adherent monolayers or as ultra-low adherent 3D-spheroid suspensions. Data in f-g are presented as mean ± S.D. of n = 4 biologically independent samples and are representative of n = 3 independent experiments.